

even after chemical fixation must always be considered, especially for GPI-anchored proteins and lipids.

These results show that subtle differences in fixation conditions could lead to large variations in the extent of immobilization of molecules, and thereby in the extent of antibody-induced clustering<sup>5,6</sup>, which might result in apparently contradictory localization data. Our advice is to fix specimens with 4% paraformaldehyde with 0.2% glutaraldehyde at 25 °C for 30 min or longer, or with cold methanol, and to consider the possibility that up to 20% of the molecules of interest could still be clustered by antibodies after fixation. For fluorescence microscopy, it would be better to observe live cells using fluorescent protein-conjugated molecules or monovalent fluorescent probes (organic dye-labeled fragment antigen-binding (Fab) fragments). Furthermore, these probes can be used without secondary antibodies even with chemical fixation.

Note: Supplementary information is available on the Nature Methods website.

#### ACKNOWLEDGMENTS

We thank R. Bittman of the City University of New York for providing Bodipy488-cholesterol, and the members of the Kusumi laboratory for helpful discussions.

#### COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

PUBLISHED ONLINE 3 OCTOBER 2010; DOI:10.1038/NMETH.F.314

Kenji A K Tanaka<sup>1,6</sup>, Kenichi G N Suzuki<sup>2,6</sup>, Yuki M Shirai<sup>1</sup>, Shusaku T Shibutani<sup>1</sup>, Manami S H Miyahara<sup>1</sup>, Hisae Tsuboi<sup>1</sup>, Miyako Yahara<sup>1</sup>, Akihiko Yoshimura<sup>3</sup>, Satyajit Mayor<sup>4</sup>, Takahiro K Fujiwara<sup>5</sup> & Akihiro Kusumi<sup>1,5</sup>

<sup>1</sup>Membrane Mechanisms Project, International Cooperative Research Project, Japan Science and Technology Agency (JST), Institute for Integrated Cell-Material Sciences (iCeMS) and Research Center for Nano Medical Engineering, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan.

<sup>2</sup>Precursory Research for Embryonic Science and Technology, JST, iCeMS, Kyoto University, Kyoto, Japan. <sup>3</sup>Department of Microbiology and Immunology, School of Medicine, Keio University and Core Research for Evolutional Science and Technology, JST, Tokyo, Japan. <sup>4</sup>National Centre for Biological Sciences, Bangalore, India. <sup>5</sup>Center for Meso-Bio Single-Molecule Imaging, iCeMS, Kyoto University, Kyoto, Japan. <sup>6</sup>These authors contributed equally to this work. e-mail: akusumi@frontier.kyoto-u.ac.jp

1. Sabatini, D.D., Bensch, K. & Barnett, R.J. *J. Cell Biol.* **17**, 19–58 (1963).
2. Karnovsky, M.J. *J. Cell Biol.* **27**, 137A–138A (1965).
3. Kusumi, A. & Suzuki, K. *Biochim. Biophys. Acta* **1746**, 234–251 (2005).
4. Mayor, S., Rothberg, K.G. & Maxfield, F.R. *Science* **264**, 1948–1951 (1994).
5. Wilson, B.S. *et al. Mol. Biol. Cell* **15**, 2580–2592 (2004).
6. Lillemeier, B.F. *et al. Proc. Natl. Acad. Sci. USA* **103**, 18992–18997 (2006).

## Federal policy and the use of pluripotent stem cells

**To the Editor:** In March 2009, US President Barack H. Obama ended eight years of restrictions on federal funding for human embryonic stem cell (hESC) research<sup>1</sup>. Obama's policy expanded funding for research and directed the US National Institutes of Health (NIH) to develop a process for certifying the ethical derivation of any line submitted to an NIH registry, including a recertification of lines approved during the George W. Bush administration (NIH Human Embryonic Stem Cell Registry Under Former President Bush, 9 August 2001–9 March 2009). What little relief the policy provided to researchers was dashed

in August 2010 when a US district court temporarily barred the use of federal funds for any type of hESC research<sup>2</sup>.

How does protracted controversy in an uncertain policy environment impact scientists working with hESCs? We began to answer this question by using information we gathered at the June 2010 International Society for Stem Cell Research (ISSCR) meeting in San Francisco. Our results, taken from 120 short surveys of researchers and an analysis of 381 research posters using hESC and human induced pluripotent stem cell (iPSC) lines, show how policies may impact the trajectory of a scientific field. Information taken from posters included the cell line name, funding sources, location of first and last authors, and whether the research used embryonic or induced pluripotent cells. Our surveys asked four basic questions: (i) “why did you choose these cell lines?”; (ii) “how did you get them?”; (iii) “why did you use iPSC lines?”; and (iv) “how important were federal and state policies in your thinking about which cell lines to use?”.

It appears that iPSCs do not yet offer a solution for a field seeking an alternative to lines derived from human embryos: 53% of the projects described on posters (203 projects) used hESCs alone and 90 of 178 iPSC projects also used hESC lines as controls or comparisons. The apparent reliance of much iPSC research on hESC lines suggests that policy decisions about hESC research will also shape the future of iPSC science<sup>3</sup>.

We also examined the type of hESC lines used, their frequency of appearance on the ISSCR posters, and their status under the Bush and Obama administrations. Forty-three different hESC lines had been used in two or more projects, and an additional 81 lines had been used in just one project each. Of the 43 lines, most (33 lines, 76.6%) were not listed on the Obama registry (NIH Human Embryonic Stem Cell Registry) (**Fig. 1**). Most studies used one or more of seven lines approved during the Bush era (281 studies, 78.83%). Four of these seven lines are currently ineligible for funding under the Obama policy. The remaining three—H1, H7 and H9—appeared in 185 experiments, which is over 63% of the total. In prior work examining materials transfer agreements and publication data, we found that the use of these three lines underpin the bulk of hESC research<sup>4</sup>. The growing diversity of human stem cell materials we observed here is good news, but the relative lack of use of new lines approved under the Obama policy presages trouble.

Much of the diversity of cell lines reported at the meeting results from research conducted outside the United States. More than half of the research had US-based first and last authors (164 projects, 55.97%). The remainder either had both first and last authors affiliated with non-US organizations or represented collaborations between a US author and researchers abroad (129 projects, 44.03%). We take the latter two cases to represent instances in which at least one of the major contributors works in a setting where American stem cell policies do not apply.

Consider the H1, H7 and H9 lines. More than 57% of US-based research (94 projects) used one or more of the three lines, compared to just over 32% of non-US and collaborative projects (42 projects), a difference that is highly significant ( $Z = 4.218$ ,  $P < 0.0001$ ). We believe this difference represents the legacy of the Bush years, followed by uncertainty created in implementing the Obama policy. The large numbers of experiments using the H1, H7 and H9 lines may reflect researchers' certitude about Bush-era lines being grandfathered into the new, more permissive regime. But anticipation of approval does not necessarily lead American


scientists to gamble with new materials. Only 14 US-based studies (8.54%) used lines that were approved under the Obama policy but not under Bush. We note, however, that these figures may not reflect future trends of researchers submitting newly derived lines for NIH review.

More than 75 cell lines have been approved for federal funding under the Obama regime. Although this is a more than threefold increase over the number of cell lines approved during the prior decade, our data suggest that, at least to date, the penetration of new materials has been hindered by scientists' tendency to favor lines that are broadly used. Based on our surveys, the number and range of newly derived lines reflect researchers' drive to use lines with greater diversity, reliance on non-Federal funding and, in the case of 129 non-US-based and collaborative projects, the use of hESC lines in locales where American policies do not apply.

Our data offer clues about the challenges created by US stem cell policy. If policies are implemented in a contradictory, piecemeal or temporary fashion, even the best-intentioned initiatives may run counter to their intended purposes, driving research to other countries and researchers to other careers. Our findings suggest that scientists will need incentives to expand the volume and diversity of research using hESCs or iPSCs. Scientific work is a gamble, uncertain and time-consuming. Stem cell researchers will more likely make such bets under more stable policy and funding arrangements. Recent events suggest that only an explicit judicial refutation of the district court's ruling or swift legislative action will set the stage for a successful expansion of stem cell biology and regenerative medicine in the United States.

#### ACKNOWLEDGMENTS

We thank the scientists who spoke with us, and J. Ostergren, R.J. Vann, L. Ooi and M. Feret for help with data collection and research assistance. C.T.S. was supported by a US National Science Foundation (NSF) grant (SBE-0949708) and The Stanford Institute for Stem Cell Biology and Regenerative Medicine.



**Figure 1** | Frequency of appearance of research using hESC lines on posters at the ISSCR conference in 2010. The lines shown are those that appear on two or more posters. Registry approval is indicated.

J.B.M was supported by an NSF grant (SBE 0949708) and NIH National Center for Research Resources (UL1 RR024150-4). J.O.-S. was supported by NSF grants (SBE-0949708 and SES-0545634).

#### COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

**Christopher Thomas Scott<sup>1,2</sup>, Jennifer B McCormick<sup>3</sup>, Mindy C DeRouen<sup>1,2</sup> & Jason Owen-Smith<sup>4</sup>**

<sup>1</sup>Program on Stem Cells and Society, Stanford University, Stanford, California, USA. <sup>2</sup>The Stem Cell Advisors, Inc., Palo Alto, California, USA. <sup>3</sup>Divisions of General Internal Medicine and Health Care Policy Research, Mayo Clinic, Rochester, Minnesota, USA. <sup>4</sup>Sociology and Organizational Studies, University of Michigan, Ann Arbor Michigan, USA. e-mail: cscott@stanford.edu or jdjos@umich.edu

1. Administration of Barack H. Obama. Executive order 13505 (9 March 2009).
2. Anonymous. *Nat. Methods* **7**, 769 (2010).
3. Scott, C.T., McCormick, J.B. & Owen-Smith, J. *Nat. Biotechnol.* **27**, 696–697 (2009).